Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pyng Medical Corp's FASTResponder Receives CE Mark In Europe And Cleared By FDA For Marketing In United States

Thursday, 27 Jun 2013 07:04pm EDT 

Pyng Medical Corp announced that FASTResponder, its Intraosseus Infusion device, has received the CE Mark in Europe and has been cleared by the United States Food and Drug Administration (FDA) for marketing in the United States. The FASTResponder product has received initial positive input from medical professionals regarding it being easy to learn and easy to use. Such feedback indicates the possibility of opening up usage of Pyng Intraosseus Infusion products to a wider range of applications and markets. 

Company Quote

0.0 +0.00%
24 Dec 2014